Developing 21st Century Medicines
ABOUT
Our Story
SMDG was founded on a simple belief: transformative medicines begin with a deeper understanding of disease biology. Guided by decades of pioneering research, we are developing proprietary platforms designed to enable the next generation of precision therapeutics.
Our multidisciplinary team combines expertise in disease biology, biomarker discovery, nanomedicine, and drug delivery to develop first-in-class disease-modifying therapies for neurological, inflammatory, oncological, and other diseases with significant unmet medical needs. Through scientific innovation and global collaboration, we are committed to translating breakthrough discoveries into medicines that have the potential to improve the lives of patients and their families.
Who We Are
SMDG Today
Today, SMDG is a UK–US biotechnology company developing targeted, peptide-based therapeutics for neurological, rare pediatric, inflammatory and oncological diseases. Our proprietary NanoLigand™ platforms combine biological target recognition and self-assembly to support the development of medicines incorporating a range of therapeutic agents, including nucleic acids.
Our multidisciplinary team and global network bring together expertise in disease biology, nanomedicine, drug discovery, immune safety and translational development. Through internal programs and strategic collaborations, we are advancing pioneering science toward new therapies for diseases with significant unmet medical need.
Our Mission and Vision
Our Mission
To develop targeted, potentially disease-modifying therapies for neurological, rare pediatric, inflammatory and oncological diseases with significant unmet medical need.
Our Vision
To translate pioneering science into safer, more effective and accessible medicines that improve the lives of patients and their families.
How We Work
We do this through rigorous science, multidisciplinary research and global collaboration. We bring together expertise in disease biology, biomarker discovery, nanomedicine, drug discovery, immune safety and translational development to advance new medicines. Our work is strengthened by global collaboration with researchers, clinicians, patient communities and strategic partners.
